Received: 31 May 2020
Accepted: 3 July 2020
First Online: 14 July 2020
Ethics approval and consent to participate
: This study was performed in accordance with the Declaration of Helsinki and International Conference on Harmonization Guidelines for Good Clinical Practice (IRB: GCO#: 11-1433).
: Not applicable.
: A.C.: Advisory board and consulting fees from Amgen, Antegene, Celgene, Janssen, Karyopharm, Millennium/Takeda, Novartis Pharmaceuticals, Oncopeptides, Sanofi; research funding from Amgen, Celgene, Janssen, Millennium/Takeda, Novartis Pharmaceuticals, Pharmacyclics. S. J.: Advisory board and consulting fees from Celgene, Bristol-Myers Squibb, Janssen Pharmaceuticals and Merck. H. J. C: Employed by the Multiple Myeloma Research Foundation, advisory board and consulting fees from Genetech, Celgene, Bristol Myers Squibb, GlaxoSmithKline and received research funding from Takeda, Celgene, and Genetech. D. M.: Advisory board and consulting fees from Janssen, Celgene, Bristol Myers Squibb, Takeda, Legend, GlaxoSmithKline, Kinevant, and Foundation Medicine. B.W.: Consulting fees from Sanofi Genzyme. J. R.: Speaking fees from Celgene and Janssen, advisory board and consulting fees from Celgene, Janssen, Bristol Myers Squibb, Oncopeptides, Adaptive Biotechnologies, X4 Pharmaceuticals, Karyopharm, and Antegene. S. P.: Consulting fees from Foundation Medicine, research funding from Celgene and Karyopharm, supported by 1R01CA244899-01A1. All other authors declare no potential conflict of interest<b>.</b>